Genetron Health and Siemens Healthcare reached a strategic cooperation to jointly promote precision diagnosis and treatment of lung cancer

In the 2021 China International Medical Equipment Fair (CMEF), Genetron Health (Nasdaq: GTH) announced a strategic cooperation with Siemens Medical - the two parties will work together to promote the Genetron S5 gene sequencer (National Machinery Note 20193220820) , Hereinafter referred to as "GENETRON S5") and Genetron Health Human 8 Gene Mutation Joint Detection Kit (Semiconductor Sequencing Method) (National Instruments Note 20203400072, hereinafter referred to as "Lung Cancer 8 Gene Kit") has been applied on a large scale in the Chinese hospital market.
More patients with non-small cell lung cancer (NSCLC) will bring efficient and accurate individualized diagnosis and treatment services, and promote the standardization of molecular testing in hospitals
.

Genetron Health Co-founder and CEO Wang Sizhen and Siemens Healthcare Asia Pacific President Elisabeth Staudinger attended the strategic cooperation signing ceremony and expressed their expectations and blessings for this cooperation
.

Wang Sizhen, the co-founder and CEO of Genetron Health, said: "Genetic Health focuses on the innovation, clinical translation, and commercialization of cancer genomics technology, and its expertise in LDT (Clinical Laboratory Self-built Project) and IVD (In Vitro Diagnostic Products) ) In the dual business model, breakthroughs have been continuously made.
This time we are very pleased to join hands with Siemens Healthcare to open a new cooperation model in the field of IVD to help the diagnosis and treatment of high-incidence cancer patients in China and the development of industry standardization, making molecular diagnosis more efficient To create social value
.

Guo Yiming, Vice President of Diagnostic Systems for Siemens Healthcare Greater China, said: “Siemens Healthcare has always been committed to serving patients.
In addition to continuously bringing international advanced testing instruments and reagents to China, it also cooperates with outstanding Chinese innovative technology companies to provide personalized diagnosis.
Technology and products to help Chinese cancer patients achieve high-quality diagnosis and treatment
.

At present, lung cancer has become one of the major disease burdens in China, and its morbidity and mortality rate ranks first among cancers
.

Equipped with the original patented technology of Genetron Health's "one-step method" (Chinese invention patent ZL 201710218529.
4), Genetron's Lung Cancer 8-Gene Kit detects multiple variant types and multiple mutations of 8 genes closely related to the targeted therapy of non-small cell lung cancer patients.
Each site can provide patients with rapid and accurate molecular typing, medication guidance and drug resistance monitoring.
Combined with GENETRON S5, it has obvious advantages in detection efficiency, ease of use, economic cost, sample starting volume, etc.
, which can be realized The fastest two-day testing cycle is suitable for independent clinical molecular testing in hospitals at all levels in China; at the same time, tumor-assisted diagnosis is also an important clinical promotion direction of Siemens Medical - Siemens Medical has hospital market resources and a mature sales team covering the whole country
.